The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD)
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD)
Authors
Keywords
-
Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2022-06-05
DOI
10.1093/jac/dkac172
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing Klebsiella pneumoniae (KPC-Kp) in Persistently Neutropenic Rabbits
- (2020) Ruta Petraitiene et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections: Lessons Learned from the Development of Ceftazidime-Avibactam
- (2020) Jianguo Li et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- An amphipathic peptide with antibiotic activity against multidrug-resistant Gram-negative bacteria
- (2020) Alysha G. Elliott et al. Nature Communications
- Avibactam Sensitizes Carbapenem-Resistant NDM-1-Producing Klebsiella pneumoniae to Innate Immune Clearance
- (2019) Erlinda R Ulloa et al. JOURNAL OF INFECTIOUS DISEASES
- Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia
- (2019) Shampa Das et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA–Specified End Points
- (2019) Antoni Torres et al. Open Forum Infectious Diseases
- Selecting the dosage of ceftazidime–avibactam in the perfect storm of nosocomial pneumonia
- (2019) Shampa Das et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Avibactam Pharmacokinetic/Pharmacodynamic Targets
- (2018) Wright W. Nichols et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A mathematical model-based analysis of the time–kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosa
- (2018) Sherwin K B Sy et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
- (2018) Antoni Torres et al. LANCET INFECTIOUS DISEASES
- Ceftazidime-Avibactam Susceptibility Breakpoints Against Enterobacteriaceae and Pseudomonas aeruginosa
- (2018) Wright W. Nichols et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups
- (2018) Jianguo Li et al. CTS-Clinical and Translational Science
- A model-based analysis of pharmacokinetic–pharmacodynamic (PK/PD) indices of avibactam against Pseudomonas aeruginosa
- (2018) S.K.B. Sy et al. CLINICAL MICROBIOLOGY AND INFECTION
- In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase–producing Klebsiella pneumoniae
- (2018) Wenxia Zhang et al. Antimicrobial Resistance and Infection Control
- In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products
- (2017) Carlos A. Rodriguez et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia
- (2017) Xinyu Qin et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Efficacy of ceftazidime–avibactam in a rat intra-abdominal abscess model against a ceftazidime- and meropenem-resistant isolate of Klebsiella pneumoniae carrying blaKPC-2
- (2017) Taryn Sleger et al. JOURNAL OF CHEMOTHERAPY
- Pharmacodynamics of Ceftolozane Combined with Tazobactam againstEnterobacteriaceaein a Neutropenic Mouse Thigh Model.
- (2016) M. J. Melchers et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients
- (2016) John S. Bradley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
- (2016) Florian M. Wagenlehner et al. CLINICAL INFECTIOUS DISEASES
- Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
- (2016) John E. Mazuski et al. CLINICAL INFECTIOUS DISEASES
- Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
- (2016) Yehuda Carmeli et al. LANCET INFECTIOUS DISEASES
- The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria
- (2016) C.M. Pillar et al. LETTERS IN APPLIED MICROBIOLOGY
- Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs
- (2016) Anders N. Kristoffersson et al. PHARMACEUTICAL RESEARCH
- Pharmacokinetics and Penetration of Ceftazidime and Avibactam into Epithelial Lining Fluid in Thigh- and Lung-Infected Mice
- (2015) Johanna Berkhout et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection
- (2015) Johanna Berkhout et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroAntibacterial Activity of the Ceftazidime-Avibactam Combination against Enterobacteriaceae, Including Strains with Well-Characterized β-Lactamases
- (2015) Premavathy Levasseur et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Optimization of human dose prediction by using quantitative and translational pharmacology in drug discovery
- (2015) Tjerk Bueters et al. Future Medicinal Chemistry
- Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam
- (2015) Renu Singh et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In VivoEfficacy of Humanized Exposures of Ceftazidime-Avibactam in Comparison with Ceftazidime against Contemporary Enterobacteriaceae Isolates
- (2014) Shawn H. MacVane et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of a Ceftazidime-Avibactam Combination in a Murine Model of Septicemia Caused by Enterobacteriaceae Species Producing AmpC or Extended-Spectrum β-Lactamases
- (2014) Premavathy Levasseur et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacodynamics of Imipenem in Combination with β-Lactamase Inhibitor MK7655 in a Murine Thigh Model
- (2014) Eleftheria Mavridou et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- UnexpectedIn VivoActivity of Ceftazidime Alone and in Combination with Avibactam against New Delhi Metallo-β-Lactamase-Producing Enterobacteriaceae in a Murine Thigh Infection Model
- (2014) Shawn H. MacVane et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Bactericidal Activity, Absence of Serum Effect, and Time-Kill Kinetics of Ceftazidime-Avibactam against β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa
- (2014) Tiffany R. Keepers et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity of Ceftazidime-Avibactam Combination inIn VitroCheckerboard Assays
- (2014) Johanna Berkhout et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model
- (2014) Ken Coleman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- -Lactamase inhibition by avibactam in Mycobacterium abscessus
- (2014) V. Dubee et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacies of Ceftazidime-Avibactam and Ceftazidime against Pseudomonas aeruginosa in a Murine Lung Infection Model
- (2013) Seth T. Housman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Pharmacodynamics of Antipseudomonal Cephalosporins in Patients with Ventilator-Associated Pneumonia
- (2013) Shawn H. MacVane et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Background and Rationale for Revised Clinical and Laboratory Standards Institute Interpretive Criteria (Breakpoints) for Enterobacteriaceae andPseudomonas aeruginosa:I. Cephalosporins and Aztreonam
- (2013) Michael N. Dudley et al. CLINICAL INFECTIOUS DISEASES
- Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial
- (2013) Christopher Lucasti et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- ComparativeIn VitroandIn VivoEfficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa
- (2012) Jared L. Crandon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Novel Modeling Framework To Guide Design of Optimal Dosing Strategies for β-Lactamase Inhibitors
- (2012) Pratik Bhagunde et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study
- (2012) José A. Vazquez et al. CURRENT MEDICAL RESEARCH AND OPINION
- Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia
- (2012) A. E. Muller et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pharmacodynamics of β-Lactamase Inhibition by NXL104 in Combination with Ceftaroline: Examining Organisms with Multiple Types of β-Lactamases
- (2011) Arnold Louie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors
- (2011) Ken Coleman CURRENT OPINION IN MICROBIOLOGY
- Evaluation of Ceftazidime and NXL104 in Two Murine Models of Infection Due to KPC-ProducingKlebsiella pneumoniae
- (2010) Andrea Endimiani et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients
- (2010) J. A. Roberts et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic–pharmacodynamic models with Monte Carlo simulation
- (2008) Christopher R. Frei et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started